Immucor, a provider of automated instrument-reagent systems to the blood transfusion industry, has submitted a pre-market notification for its Galileo instrument to the FDA.

That Atlanta-based company submitted the information on Jan. 30.

Commenting on the submission, Edward Gallup, chairman and chief executive officer of Immucor, stated, “We are very pleased to have filed this submission and look forward to marketing the instrument in the United States.”

The Galileo was launched in Europe in June of 2002 and at the end of November 2003, the company had 93 placements.

Founded in 1982, Immucor manufactures and sells a line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion.